Articles
I L-17, also known as IL-17A, is a key signature cytokine of type 17 helper T cells and is also produced by innate immune cells [1] [2] [3] . IL-17A plays a critical role in the pathogenesis of autoimmune and inflammatory diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis and asthma [4] [5] [6] .
IL-17A signals through a heterodimeric receptor complex (IL-17R) composed of IL-17RA and IL-17RC 7, 8 . Both IL-17RA and IL-17RC belong to the SEFIR protein family, which is defined by the presence of a conserved cytoplasmic SEFIR domain 9 . Act1 (encoded by the gene TRAF3IP2, also known as CIKS) is an essential component in IL-17 signaling and is also a member of the SEFIR protein family [10] [11] [12] . After IL-17 stimulation, Act1 is recruited to IL-17R through a SEFIR-dependent interaction. Act1 in turn engages members of the TRAF family, activating the NF-κ B, C/EBP and MAPK signaling pathways. IL-17-Act1-mediated signaling results in transcription of genes encoding proinflammatory and neutrophilmobilizing cytokines and chemokines, including Cxcl1, Tnf, Il6 and Csf2 (ref. 13 ).
Although IL-17 activates gene transcription of cytokines and chemokines, it is equally important for IL-17 to stabilize otherwise unstable mRNAs for the induction of expression of proinflammatory genes. Cytokine and chemokine mRNAs have short half-lives because of conserved cis elements, including AU-rich elements (AREs) and stem-loop structures in their 3′ UTRs 14, 15 . The AREs within the 3′ UTRs can be recognized by RNA-binding proteins (including TTP, AUF1, KSRP and SF2) that mediate the sequential deadenylation, decapping and exonucleolytic degradation of RNA 16, 17 . Stem-loops are present in immunologically related mRNAs (including Tnf and Il6) and are destabilized by the RNAbinding proteins Roquin and Regnase-1. Stress granules form in response to stress, store mRNAs stalled in translation and transfer them to processing (P) bodies for degradation. Roquin destabilizes translationally inactive mRNAs accumulated in P bodies and stress granules, whereas Regnase-1 specifically cleaves and degrades translationally active mRNAs bound to polysomes 18 . Although multiple mRNA-destabilizing mechanisms have been discovered, little is understood about the stabilization of mRNAs encoding inflammatory factors. Although the ARE-binding protein SF2 and human antigen R (HuR) have previously been implicated in IL-17-induced mRNA stabilization, the recruitment of SF2 and HuR cannot explain the receptor-specific mRNA stabilization of select inflammatory genes 19, 20 .
Here, we demonstrate that Act1 behaves as an RNA-binding protein that interacts with the stem-loop structure of select inflammatory mRNAs, such as Cxcl1, Tnf and Csf2. Act1 binding results in stabilization of the mRNA and thereby mediates the proinflammatory effects of IL-17 signaling. RNA aptamers containing the stem-loop structure (referred to herein as SBE) inhibited Act1's binding to target mRNAs, attenuated IL-17-mediated mRNA stabilization and ameliorated pathology in mouse models of asthma IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling Tomasz Herjan 1,2,9 , Lingzi Hong 1,9 , Jodi Bubenik 3 Mechanisms that degrade inflammatory mRNAs are well known; however, stabilizing mechanisms are poorly understood. Here, we show that Act1, an interleukin-17 (IL-17)-receptor-complex adaptor, binds and stabilizes mRNAs encoding key inflammatory proteins. The Act1 SEFIR domain binds a stem-loop structure, the SEFIR-binding element (SBE), in the 3′ untranslated region (UTR) of Cxcl1 mRNA, encoding an inflammatory chemokine. mRNA-bound Act1 directs formation of three compartmentally distinct RNA-protein complexes (RNPs) that regulate three disparate events in inflammatory-mRNA metabolism: preventing mRNA decay in the nucleus, inhibiting mRNA decapping in P bodies and promoting translation. SBE RNA aptamers decreased IL-17mediated mRNA stabilization in vitro, IL-17-induced skin inflammation and airway inflammation in a mouse asthma model, thus providing a therapeutic strategy for autoimmune diseases. These results reveal a network in which Act1 assembles RNPs on the 3′ UTRs of select mRNAs and consequently controls receptor-mediated mRNA stabilization and translation during inflammation.
Results

IL-17 induces distinct Act1
RNPs in the nucleus and cytoplasmic granules. mRNAs that are not engaged in translation can aggregate into cytoplasmic messenger RNP granules referred to as P bodies and stress granules 21, 22 . IL-17A stimulation induced the assembly of Act1, the key adaptor of IL-17R, into microscopically visible cytoplasmic granules and nuclear localization ( Fig. 1a and ref. 23 ). Act1 colocalized with the decapping enzyme Dcp1, a component of P bodies (Fig. 1b ), but not with TIA1 (a marker of stress granules) or the IL-1R-associated kinase IRAK1 (Fig. 1b) . To investigate IL-17A-induced interaction of endogenous Act1 with Dcp1, we generated LSL-hemagglutinin tag (HA)-Act1 knock-in mice by knocking a LoxP-stop-LoxP-Traf3ip2 cDNA-HA-poly(A) cassette into the endogenous Act1 locus ( Supplementary Fig. 1a and Methods). Using mouse embryonic fibroblasts (MEFs) isolated from UBC-Cre-ERT2/LSL-HA-Act1 f/+ mice, we detected the interaction between the endogenous HA-Act1 and Dcp1 in response to IL-17A stimulation by using in situ proximity ligation assays (Supplementary fig. 1b ) and coimmunoprecipitation ( Fig. 1c ). RNase pretreatment of the lysates abolished the Act1-Dcp1 interaction ( Fig. 1c) , thus implicating a possible role of the IL-17-Act1 axis in mRNA metabolism in P bodies.
In addition to Act1-Dcp1 interaction, IL-17A induced interaction of HA-Act1 with SF2 and HuR in the nucleus and cytoplasmic granules, respectively ( Supplementary Fig. 1c and ref. 20 ). However, IL-17A stimulation did not induce visible interaction of Dcp1 with SF2 and HuR in either the nucleus or the cytoplasm ( Supplementary  Fig. 1c -f). These results indicated that Act1's interaction with Dcp1 in the P bodies was likely to be independent of the Act1-SF2 and Act1-HuR complexes. Notably, RNase pretreatment of the lysates abolished the Act1-SF2 and Act1-HuR interaction ( Fig. 1c and Supplementary Fig. 1d-f ). Together, these results implicate the IL-17-Act1 axis in mRNA metabolism via formation of distinct Act1-containing RNPs, including Act1-SF2 (RNP1), Act1-Dcp1 (RNP2) and Act1-HuR (RNP3). As a control, we showed that whereas IL-17E (also known as IL-25, another member of the IL-17 family) also induced the formation of Act1 RNPs (interaction with SF2, Dcp1 or HuR), IL-1 stimulation did not induce the formation of Act1 RNPs (interaction with SF2, Dcp1 or HuR) (data not shown).
The SEFIR domain of Act1 is required for the formation of Act1
RNPs. Deletion analysis showed that the SEIFR domain of Act1 was necessary and sufficient for Act1 assembly into granules and colocalization with Dcp1 ( Fig. 1d and Supplementary Fig. 1g ). Although SEFIR3 (residues 463-501) of Act1 is required for interaction with IL-17R 24 , Δ SEFIR3 still localized to the P bodies ( Fig. 1d and Supplementary Fig. 1g ). Whereas Δ SEFIR5 showed decreased colocalization with P bodies, Δ SEFIR1 showed no localization to the P bodies ( Fig. 1d and Supplementary Fig. 1g ). Δ SEFIR1 also did not interact with Dcp1, SF2 and HuR in the coimmunoprecipitation experiment (Fig. 1e ). However, both Δ SEFIR1 and Δ SEFIR5 retained their ability to interact with IL-17R (data not shown). Together, these results indicated that the SEFIR domain of Act1 is required for the formation of Act1 RNPs.
Act1 directly binds the Cxcl1 3′ UTR through the SEFIR domain.
We then modeled the SEFIR domain of Act1 with SWISS-Model (http://swissmodel.expasy.org/), using the crystal structure of IL-17RA SEFIR as a template. Helix α A from SEFIR1 and helix α E from SEFIR5 are located in proximity in the Act1 SEFIR domain, forming a positively charged surface ( Fig. 2a ). The corresponding helix α A and helix α E from IL-17RA are not located on the same surface, and helix α E is negatively charged ( Fig. 2a ). We reasoned that the SEFIR1 and SEFIR5 positively charged surface in Act1 might provide an interaction interface with negatively charged mRNAs. To test this possibility, we subjected Act1 SEFIR and IL-17RA SEFIR to RNA electrophoretic mobility shift assays (REMSAs) on the Cxcl1 3′ UTR, which has been shown to be regulated by the IL-17-Act1 axis for stabilization of Cxcl1 mRNA 25, 26 . Recombinant Act1 SEFIR, but not IL-17RA SEFIR, bound to the Cxcl1 probe with a dissociation constant (K d ) of 50.2 ± 7.8 nM ( Fig. 2b and Supplementary Fig. 2a ). Act1 SEFIR did not bind the GC-rich 3′ UTR of Gpx4 mRNA (Fig. 2b) . Whereas Δ SEFIR2, Δ SEFIR3 and Δ SEFIR4 retained the ability to bind RNA, Δ SEFIR1 and Δ SEFIR5 exhibited substantially lower binding to RNA ( Supplementary Fig. 2b-f ). Mutation of the positively charged amino acid residues in SEFIR1 (K407A) or SEFIR5 (K524A K526A K527A) substantially decreased the binding of Act1 SEFIR to RNA, whereas the K407A K524A K526A K527A mutant (SEFIR1 + 5mt) exhibited abolished RNA binding ( Fig. 2c ), thus supporting the proposed RNA-interaction interface of Act1 SEFIR in Fig. 2a . The impaired RNA binding of Act1 mutants (Δ SEFIR1 and SEFIR1 + 5mt) correlated with their inability to enter the P bodies ( Fig. 1d and Supplementary Fig. 1g ) and form RNPs ( Fig. 1e and Supplementary Fig. 1d -f), a result consistent with the RNA-dependent interaction of Act1 with Dcp1, SF2 and HuR shown in Fig. 1c .
Act1 SEFIR binds a stem-loop structure in the Cxcl1 3′ UTR.
In agreement with the observation that Act1 SEFIR bound nt 720-940 (Cxcl1 220, Figs. 2b and 3a), wild-type Act1, but not Act1 Δ SEFIR1 and Δ SEFIR mutants, stabilized reporter mRNA under the control of 3′ UTR-Cxcl1 220 in HeLa Tet-Off cells ( Supplementary  Fig. 4a ). Act1 SEFIR bound nt 780-900 (Cxcl1 120) of the Cxcl1 3′ UTR with similar affinity (Fig. 3a,b ). Secondary-structure prediction (RNAfold web server, http://rna.tbi.univie.ac.at/cgi-bin/ RNAWebSuite/RNAfold.cgi/) indicated that nt 780-900 might form a secondary structure with four stem-loops (denoted A-D, Fig. 3b ). We narrowed down the Act1-binding region to nt 810-857 (Cxcl1 47; Fig. 3a,b) , an evolutionarily conserved region retaining stemloops B and C ( Fig. 3a ), denoted the SBE (Fig. 3a ,c). Binding of Act1 to the SBE was confirmed with surface plasmon resonance, which revealed a K d of 59.5 nM ( Supplementary Fig. 4b ). Whereas disruption of stem-loop B did not affect Act1 SEFIR binding, impairment of stem-loop C completely prevented binding of Act1 SEFIR (Fig. 3c ). Likewise, IL-17A stimulation did not attenuate Cxcl1 mRNA decay in HeLa Tet-Off cells transfected with stem-loop C mutant ( Fig. 3d ). Together, the structure-function data suggested that Act1 SEFIR's binding to stem-loop C in the 3′ UTR of Cxcl1 is required for IL-17A-induced Cxcl1 mRNA stabilization.
To further map the Act1 SEFIR-binding site, we performed enzymatic RNA footprinting on the Act1 SEFIR-SBE complex. Nucleotides involved in the Act1-SBE interaction were identified through partial digestion of the SBE RNA, which was performed in the absence or presence of Act1 SEFIR. The native RNA and RNA-protein complexes were then partially digested with different RNases and analyzed by electrophoresis. The cleavage results with the native RNA ( Fig. 3e ) were consistent with the predicted structure shown in Fig. 3c . RNase A cleaves at single-stranded C and U bases (yellow in Fig. 3f ). RNase T1 cleaves after single-stranded G bases (purple in Fig. 3f ). RNase V1 cleaves in double-stranded regions (blue in Fig. 3f ). Several nucleotides (U19, C31 and U33) were cleaved with both single-stranded and double-stranded nucleases, thus suggesting that these regions may 'breathe' , which means that RNA nucleotides from this region may become transiently accesible. When the SBE was incubated with Act1 SEFIR, we observed partial protection of specific nucleotides from cleavage by RNase A (U36 and U41-44) and RNase V1 (27-29, C31 and 36-40) ( Fig. 3e ). Minor protection between nucleotides 19 and 23 was occasionally observed, but the results were not consistent between experiments. Interestingly, bases U10-12 became more accessible to RNase A cleavage, thus suggesting that Act1 binding to stem-loop C may cause conformational changes in stem-loop B (bracket in Fig. 3e ).
Together, the footprinting results validated that stem-loop C is the contact site for Act1 SEFIR. Disruption of the stem in stem-loop C (replacing CCC with GGG) abolished the binding of Act1 SEFIR to RNA, whereas replacement of the sequence in the stem of stemloop C did not alter the binding of Act1 SEFIR, thus indicating that it is the secondary structure rather than the primary sequence that Supplementary Fig. 1g ). Term, terminus. 50 expressing cells per plate were analyzed for quantification. e, Act1 −/− MEFs reconstituted by retroviral infection with either FLAG-tagged mouse Act1 wild type (WT) or SEFIR1-deletion mutant were treated with IL-17A (50 ng/ml). The cell lysates were immunoprecipitated with anti-FLAG, then subjected to western blot analysis with antibodies to the indicated proteins. All data are representative of two independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001; NS, not significant. Scale bars, 20 μ m. Fig. 3a ). Graph shows mean and s.d of three independent experiments. c, REMSA of purified recombinant Act1 SEFIR and SEFIR point mutants (mt) to the Cxcl1 3′ UTR (Cxcl1 220). d, FLAG-tagged Act1 WT and the indicated Act1 mutants were transfected into MEFs with V5-tagged IL-17RA. The cell lysates were immunoprecipitated with anti-V5, then subjected to western blot analyses with the indicated antibodies. Throughout figure, numbers to the right of blots indicate molecular weight (kDa). e, Act1 −/− MEFs transfected with Act1 WT and Act1 mutants were treated with IL-17A for the indicated times. The cell lysates were analyzed by western blotting with antibodies to the indicated phosphorylated (p-) proteins. f, Act1 −/− MEFs transfected with expression vectors for Act1 knockout (KO), Act1 WT or the indicated Act1 mutants were pretreated with TNF for 1 h and then either left untreated or stimulated with IL-17A. The mRNA and protein levels were analyzed by RT-PCR (top) and enzyme-linked immunosorbent assay (ELISA; bottom), respectively (n = 3 independent plates of cells). Ind, induction. g, Act1 −/− MEFs transfected with expression vectors for Act1 KO, Act1 WT or the indicated Act1 mutants were pretreated with TNF for 1 h and then treated with actinomycin D either alone (NT) or in the presence of IL-17A for 25, 50, 70, and 100 min, then subjected to RT-PCR analysis (n = 3 independent plates of cells). The indicated mRNA levels were normalized to those of Gapdh and are presented as half-life. h. Act1 −/− MEFs transfected with vector (Act1 KO), Flag-tagged Act1 WT or Act1 mutants were pretreated with TNF for 1 h, then treated with IL-17A for 0 and 60 min and subjected to anti-FLAG RNA immunoprecipitation and RT-PCR analyses of the indicated mRNAs (n = 3 independent plates of cells). Relative values to levels from IgG immunoprecipitation are shown. In f-h, bar graphs show mean and s.d. of independent plates of cells. *P < 0.05, **P < 0.01 and ***P < 0.001 (Act1 WT versus Act1 mutants or as indicated); NS, not significant. Data are representative of two (c-h) or three (b) independent experiments). Stem-loop C GGG-CCC
Cxcl1 120 plays a critical role in Act1 SEFIR recognition ( Fig. 3g ). However, the replacement of the entire loop TAA of the stem-loop C with AGU (without affecting the formation of the stem-loop) also abolished SEFIR binding, thus demonstrating the importance of the loop sequence in Act1 SEFIR's RNA binding ( Fig. 3g ).
Act1 RNA binding to 3′ UTRs inhibits decapping. The next question that we sought to address was how Act1 RNA binding in Dcp1-containing P bodies mediates IL-17A-induced stabilization of otherwise unstable mRNAs of proinflammatory genes. mRNAs are decapped by the Dcp1 and Dcp2 decapping enzymes and then degraded 5′ to 3′ by the exonuclease Xrn1 (refs 28, 29 ). Because both coimmunoprecipitation and in situ proximity ligation assay showed that Act1 binds Dcp1, we examined whether Act1 binding to Dcp1 might affect the decapping activity of the Dcp1-Dcp2 complex.
Purified Dcp1-Dcp2 and Act1 from transfected HeLa cells were incubated with the capped Cxcl1 3′ UTR (nt 720-940). There was indeed a dose-dependent inhibitory effect of Act1 (but not Δ SEFIR) on the decapping efficiency of the Dcp1-Dcp2 complex (Fig. 4a,b and Supplementary Fig. 5a ). Additionally, Act1 did not protect the stem-loop C-disruption mutant transcript from decapping, thus confirming the importance of Act1 RNA binding in Act1's inhibition of decapping ( Fig. 4a,b ).
Act1 recruits TBK1, which disrupts the decapping complex via phosphorylation of Dcp1. IL-17A stimulation induced Dcp1 phosphorylation at S315 ( Fig. 4c ), which has been shown to be required for the inactivation of the decapping activity 30, 31 . Although recent studies have reported two Act1-interacting kinases: IKKi and TBK1 (refs 32,33 ) ( Fig. 4d ), IL-17A induced interaction of only TBK1 (not IKKi) with Dcp1 ( Fig. 4c , Supplementary Fig. 1d -f and data not shown). IL-17A-induced Dcp1 phosphorylation (but not p65 phosphorylation) was diminished in TBK1-deficient cells, whereas IKKi deficiency had little effect ( Supplementary Fig. 5b ). Recombinant TBK1 phosphorylated Dcp1 in an in vitro kinase assay ( Fig. 4e ). TBK1 inhibitor blocked IL-17A-induced phosphorylation of TBK1-Dcp1 without affecting the interaction of TBK1 with Act1 or Dcp1, thus suggesting that TBK1 activation is not required for interaction with the Act1-Dcp1 complex (Fig. 4c ). TBK1 overexpression diminished the interaction between Dcp1 and Dcp2, whereas TBK1 did not remove the Dcp1 S315A mutant from Dcp2 ( Supplementary Fig. 5c ). Furthermore, TBK1 inhibitor effectively abolished Act1-mediated inhibition of decapping ( Fig. 4a .b), and immunodepletion of TBK1, but not IKKi, abolished Act1-mediated inhibition of decapping ( Supplementary Fig. 5d ,e). Moreover, TBK1 deficiency substantially decreased IL-17A-induced expression of Cxcl1, Csf2 and Tnf at both the mRNA and protein levels ( Fig. 4f ). Together, these results suggest that Act1 may bring TBK1 to the mRNA targets in the P bodies, where TBK1 phosphorylates Dcp1, thereby resulting in Dcp1 dissociation from Act1 RNP, inhibition of decapping and stabilization of mRNAs.
Act1 forms distinct RNPs with Dcp1, Dcp2, SF2 and HuR. Our results defined an Act1 RNP consisting of Act1-TBK1-Dcp1-Dcp2, which we designated RNP2. Although imaging studies have indicated that SF2 and HuR do not colocalize with Dcp1 ( Supplementary  Fig. 1c ), we performed immunoprecipitation experiments to examine the different Act1 RNPs. Whereas IL-17A induced Dcp1-Act1-TBK1 interaction in an RNA-dependent manner (sensitive to RNase treatment), SF2 and HuR were not detected in this RNP (RNP2) ( Supplementary Fig. 1d ). IL-17A-induced Act1-SF2 complex (RNP1) was also sensitive to RNase pretreatment, but Dcp1-TBK1 and HuR were not found in this Act1-SF2 RNP ( Supplementary  Fig. 1e ). Likewise, we did not detect Dcp1-TBK1 and SF2 in IL-17A-induced Act1-HuR RNP (RNP3; Supplementary Fig. 1f ).
Together, these results suggest that Act1-SF2, Act1-Dcp1-Dcp2
and Act1-HuR represent three independent RNPs. Deletion of SEFIR1 (Δ SEFIR1) abolished the formation of all three RNPs, thus implicating the importance of Act1's binding to mRNA in the formation of these Act1 RNPs ( Supplementary Fig. 1d-f ). SF2 has been shown to mediate decay of cytokine and chemokine mRNAs 34, 35 . We have reported that SF2 binds chemokine mRNA (induced by TNF) in the absence of IL-17A stimulation 36 ; however, the SF2-mRNA interaction substantially decreased after stimulation with IL-17A in an Act1-dependent manner ( Fig. 5a and Supplementary Fig. 6a ). Interestingly, we found that IL-17A did not decrease SF2's binding to Cxcl1 in Act1-deficient cells restored with Δ SEFIR1, thus suggesting that Act1's RNA binding might be required for the dissociation of SF2 from the mRNAs (Fig. 5a ). One important question is how Act1's binding to mRNAs promotes the dissociation of SF2 from mRNAs. We found that SF2 bound the same region on Cxcl1 as Act1, the SBE, and that the impairment of stem-loop C completely prevented the binding of SF2 ( Fig. 5b and Supplementary Fig. 6b ). Addition of increasing amounts of Act1 to the RNA binding reaction attenuated SF2's binding to the SBE (Fig. 5c ). Notably, SF2 phosphorylation has been implicated as a mechanism for its dissociation from mRNA targets 37 . Although both imaging and fractionation experiments indicated that Act1-SF2 RNP1 resides in the nucleus ( Supplementary  Figs. 1c and 6c ), IKKi, a kinase required for IL-17A-mediated mRNA stabilization 32 , translocated into the nucleus and was detected in Act1-SF2 RNP1 in response to IL-17A stimulation ( Supplementary  Fig. 6c ). IKKi indeed was able to phosphorylate SF2 in vitro (Fig. 5d ), and incubation of recombinant IKKi with SF2 decreased the ability of SF2 to bind Cxcl1 mRNA ( Supplementary Fig. 6d ), thus implicating IKKi in preventing SF2's binding to mRNAs. Whereas IL-17A-induced IKKi-SF2 and Act1-SF2 interaction were abolished in Act1-deficient MEFs restored with Δ SEFIR1 ( Fig. 5a and Supplementary Fig. 6c ), Act1-IKKi interaction in both the cytosol and nucleus was retained in these cells ( Supplementary  Fig. 6c ). These results suggested that IL-17A induces Act1-IKKi interaction before their translocation to the nucleus, and Act1's binding to SF2-bound mRNAs in the nucleus allows IKKi to phosphorylate SF2, thereby attenuating SF2's binding to the mRNA targets.
HuR has been implicated in shifting target mRNAs to polysomes for protein translation, and IL-17A stimulation induces the coshift of Act1-HuR to the polysomes 20, 38 . IL-17A induced the binding of HuR to Cxcl1 in Act1-expressing MEFs, and this effect was abolished in Act1-deficient MEFs restored with Δ SEFIR1, thus suggesting that Act1's RNA binding might also be required for HuR's recruitment to the target mRNAs ( Fig. 5a ). We found that HuR bound CXC1 220-I but not CXC1 220-II ( Fig. 5b and Supplementary  Fig. 6e ). HuR and Act1 were found to simultaneously bind CXC1 220 (Fig. 5e ). Removal of nt 720-829 from CXC1 220 abolished HuR binding, whereas Act1 binding was retained, thus indicating that HuR and Act1 have independent binding sequences on Cxcl1 (Fig. 5b,e ). Because HuR is not part of RNP1 (Act1-SF2) ( Supplementary Fig. 1c-f ), Act1 may facilitate HuR's binding to Cxcl1 in vivo after competing SF2 away from target mRNAs. In support of this possibility, the IL-17A-induced coshift of Act1-HuR to the polysomes 20 was abolished in Act1-deficient MEFs restored with Δ SEFIR1 (Fig. 5f-g) . The ratio of Cxcl1 mRNA in translation-active polysomes over the inactive fractions substantially decreased in Act1deficient MEFs restored with Δ SEFIR1 (Fig. 5g,h) . On the basis of these results, we propose the following model for the actions of Act1 RNA binding ( Supplementary Fig. 1h ). First, IL-17 induces Act1's binding to mRNAs (such as Cxcl1) in the nucleus (RNP1), thereby preventing SF2-mdiated mRNA decay by competing away SF2's binding to the mRNAs, an effect further promoted by IKKi-mediated SF2 phosphorylation. Second, Act1 follows the mRNAs to the P bodies (RNP2) and subsequently inhibits Dcp1-Dcp2-mediated . e, Confocal imaging of tracheas from HA-Act1 knock-in mice treated with methylated, fluorescently labeled SBE WT aptamers (red) and anti-HA stained (green). Images were acquired at 40× magnification and 63× magnification. Blue, DAPI nuclear staining. f, Relative abundance of IL-17A and IL-17E isolated from lung tissue, determined by RT-PCR analysis (n = 6 mice/group). g,h, C57BL/6 J mice were sensitized and challenged with HDM, then subjected to treatment with methylated SBE mutant C (Control or Ctrl) or SBE WT aptamer (n = 6 mice/group). Lung tissue (g) and BAL (h) were subjected to paraffin sectioning and cytospins, then hematoxylin-eosin and HEMA3 staining respectively. i, Total and neutrophil cell numbers in the BAL of the indicated mice (n = 6 mice/ group) were manually counted. j, RT-PCR analysis of Act1-target genes in the lung tissues from mice (n = 6 mice/group) treated as in e. of Act1 in the defined RNPs and in inflammatory gene expression. SBE RNA aptamer and mutant stem-loop B aptamer (but not mutant stem-loop C) were able to compete away Act1 SEFIR's binding to the Cxcl1 3′ UTR (Fig. 6a) . The transfected fluorescent SBE RNA aptamers mainly resided in the cytoplasm and were detected in Act1 granules ( Fig. 7b and Supplementary Fig. 6a ). Act1 granules substantially decreased over time in cells transfected with SBE RNA aptamers, thus suggesting that the SBE RNA aptamers might be disrupting Act1's colocalization with P bodies (Fig. 6c ). SBE RNA aptamers, but not SBE aptamers with mutated stem-loop C, abolished the formation of Act1 granules and Act1's colocalization with Dcp1 (Fig. 6c ). Furthermore, SBE RNA aptamers specifically disrupted endogenous Act1-Dcp1 and Act1-HuR interaction in the cytoplasm but had no effect on Act1-SF2 interaction in the nucleus ( Supplementary Fig. 7b ), a result consistent with the observation that SBE RNA aptamers mainly resided in the cytoplasm ( Fig. 6b and Supplementary Fig. 7a ). SBE RNA aptamers were also able to compete away Act1 SEFIR binding to the 3′ UTRs of Csf2 and Tnf mRNAs ( Fig. 6d and Supplementary Fig. 7c ), thus suggesting that the binding of SBE RNA aptamers to Act1 SEFIR blocks Act1's binding to the mRNA targets. These results suggest that the SBE RNA aptamers have the potential to be an inhibitory agent for blocking the IL-17A-induced inflammatory response. We indeed found that transfection of SBE RNA aptamers decreased IL-17A-and IL-17Emediated, but not IL-1-mediated, mRNA stabilization and the production of the chemokine CXCL1 and the cytokines GM-CSF and TNF (Fig. 6e,f and Supplementary Fig. 7d-g) .
SBE RNA aptamers inhibited IL-17A-dependent skin and lung inflammation.
Secukinumab (anti-IL-17A) has shown great efficacy in psoriasis treatment and has been approved by the US Food and Drug Administration for this application. Aberrant keratinocyte proliferation and neutrophilic inflammation are well-known hallmarks of the pathogenesis of psoriasis. We found that the SBE RNA aptamer, but not mutant aptamer, substantially decreased IL-17A-dependent epidermal hyperplasia and neutrophil infiltration in the ears (Fig. 7a-c) . Likewise, SBE RNA aptamer, but not mutant aptamer, greatly diminished IL-17A-induced expression of Cxcl1, Csf2 and Tnf in the ears (Fig. 7d ). Together, these data indicate that IL-17A induced keratinocyte proliferation and neutrophil infiltration, thus resulting in epidermal hyperplasia, and these effects were blocked by SBE RNA aptamers.
House dust mites (HDM), a natural allergen to which people with asthma are often sensitized, can induce neutrophilic airway inflammation, which is often associated with severe asthma 39 . In agreement with reports from the literature, we found that IL-17RC-knockout (but not IL-17RB-knockout) mice, compared with wild type, showed substantially less neutrophilic airway inflammation in a severe asthma model induced by high-dose HDM (ref. 40 and data not shown), during which IL-17 (but not IL-17E) was highly induced (Fig. 7f ). Tracheal section of mice subjected to intranasal administration of fluorescently labeled SBE RNA aptamers showed efficient tissue penetration of SBE RNA aptamers ( Fig. 7e ) and their colocalization with Act1 inside the cells (Fig. 7e ). We then evaluated the ability of SBE RNA aptamers to alleviate neutrophilia in this IL-17A-dependent severe asthma model. HDM-induced neutrophilia and inflammatory gene expression in bronchoalveolar lavage (BAL) and lung tissue were substantially decreased by treatment with SBE RNA aptamers ( Fig. 7g-j) . Together, the results from HDM experiments indicate a potential therapeutic role of SBE RNA aptamers in treatment of IL-17A-mediated severe asthma.
Discussion
The SEFIR domain, a conserved motif present in the cytoplasmic regions of IL-17R subunits and the adaptor Act1, mediates the recruitment of Act1 to the receptor after IL-17 stimulation. Here, we unexpectedly identified SEFIR of Act1 as a direct RNA-binding domain that allows Act1 to bind and stabilize otherwise unstable mRNAs of proinflammatory genes (Cxcl1, Csf2 and Tnf) in response to IL-17 stimulation. Act1 directly binds the 3′ UTRs of inflammatory mRNAs and forms distinct RNPs in several subcellular compartments, including P bodies, controlling mRNA metabolism. Structure-function analysis showed that Act1 SEFIR binds a stem-loop structure (termed the SBE) in the Cxcl1 3′ UTR. RNA aptamers containing the SBE abolished Act1's binding to the target mRNAs and attenuated IL-17-mediated mRNA stabilization. Furthermore, SBE RNA aptamers inhibited IL-17A-induced skin inflammation and decreased airway inflammation in an HDM-induced asthma model. Together, our results demonstrate that the receptor-proximal adaptor Act1 directly binds mRNAs and controls the steps of RNA metabolism, thus providing a novel molecular mechanism of inflammatory response via the receptor-specific mRNA stabilization of select inflammatory genes. Moreover, the discovery of a noncanonical function of Act1 should allow for the development of new therapeutic strategies for autoimmune inflammatory diseases.
We and others have previously shown that Act1 is required for IL-17R-mediated signaling including that of NF-κ B, JNK, p38 and ERK 13 . The Act1 mutants defective in RNA binding retained the ability to interact with IL-17RA and were able to mediate IL-17-induced NF-κ B, JNK, ERK and p38 activation. These data indicate a novel function of Act1 as an RNA-binding protein for mRNA stabilization, which is separate from its role as an adaptor. Using Act1 mutants defective in binding to the receptor or TRAF6, we found that the recruitment of Act1 to IL-17RA is required for IL-17-induced Act1 RNA binding in the cells, whereas Act1 binding to TRAF6 (and its ability to activate NF-κ B) is independent of Act1's RNA binding activity. This study intriguingly reveals the selective recruitment of IKKi to Act1 RNP1 (SF2 complex) and TBK1 to Act1 RNP2 (Dcp1 complex). Additionally, TBK1, but not IKKi, was required for IL-17induced Dcp1 phosphorylation. Recent studies have implied that distinct scaffold proteins assemble TBK1 and IKKi subcomplexes, in a stimulus-specific manner, thus potentially representing a mechanism to achieve specificity [41] [42] [43] [44] .
We propose the following model for the actions of Act1 RNA binding in the IL-17-induced inflammatory response. After IL-17 stimulation, multiple signaling pathways (including the NF-κ B and MAPK pathways) are activated to induce the gene transcription of cytokines and chemokines. Act1 then directly binds the mRNAs of cytokines and chemokines and consequently stabilizes these otherwise unstable mRNAs for the production of the proinflammatory mediators. Act1's binding to mRNAs of inflammatory genes results in the formation of multiple RNPs controlling different steps of mRNA metabolism. The present study provides an initial example of a receptor-interacting adaptor molecule, Act1, playing a direct role in mRNA metabolism and orchestrating receptor-mediated selectivity of mRNA stabilization and translation. Considering the efficacy of SBE RNA aptamers in blocking IL-17-dependent skin and airway inflammation, this newly found mechanism of Act1 also provides an opportunity to develop new IL-17-Act1-targeted therapeutic agents for treating inflammatory diseases.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-018-0071-9.
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Methods Animals. IKKi-deficient mice were a gift from T. Maniatis. TBK1 flox mice were obtained from Millenium Pharmaceuticals. Mice 6 weeks of age were used for primary kidney cell isolation. LSL-HA-Act1 knock-in mice were bred with UBC-Cre-ERT2 mice 45 . All mice were on the C57BL/6 N background; all protocols were approved by the Cleveland Clinic Institutional Animal Care and use Committee, and all studies were executed by following relevant ethical regulations detailed in animal-use protocols.
Cell culture and reagents. The following antibodies were used: Santa Cruz Biotechnology, anti-Act1 (sc-11444, clone H300), anti-HuR (sc-5261, clone 3A2), anti-SF2 (anti-28724, clone H-110), anti-GAPDH (sc-47724, mouse monoclonal) and anti-β -actin (sc-8432, mouse monoclonal); Sigma, anti-HA (H-9658, mouse monoclonal); Cell Signaling Technology, anti-TBK1 (3504, clone D1B4), anti-M2 (2368, rabbit polyclonal), anti-V5 (13202, rabbit polyclonal), anti-p-JNK (9251, rabbit polyclonal), anti-JNK (9252, rabbit polyclonal), anti-p-Iκ B (2859, clone 14D4), anti-p-p65 (3033, clone 93H1), anti-p65 (8242, clone D14E12), anti-Ikki (3416, clone D61F9), anti-p-IKKα /β (2697, clone 16A6) and anti-pERK (3371, rabbit polyclonal); Milipore, normal mouse IgG (12-371) and normal rabbit IgG . Antibody to p-S315 Dcp1a was kind gift from E. Izaurralde. Antibody to Dcp1 was kind gift from J. Lykke Andersen. Goat anti-rabbit IgG-HRP (Cell Signaling Technology 7074, polyclonal) and goat anti-mouse IgG-HRP (Cell Signaling Technology, 7076, polyclonal) were used as secondary antibodies for immunoblot analysis. TBK1 inhibitor MRT67307 was purchased from Sigma Aldrich. Primary MEFs were isolated from wild-type, Act1-deficient and LSL-HA-Act1 knock-in/UBC-Cre-ERT2 embryos at embryonic day 14. Cell culture of MEFs, HeLa Tet-Off cells and primary kidney epithelial cells was performed as previously described 20, 24 . Proximity-based ligation assays were performed in HeLa cells according to the manufacturer's instructions (Duolink Assay, Sigma Aldrich).
For stimulation ex vivo, cells were treated with mouse IL-17A (50 ng/ml, 421-MT, R&D Systems), human IL-17A (50 ng/ml, 317-1 ML, R&D Systems), or mouse TNF (10 ng/ml, 410-MT, R&D Systems), IL-1 (10 ng/ml, 201-LB, R&D Systems) or IL-25E (10 μ g/ml, 1399-IL, R&D Systems).
Transfection, adenoviral and retroviral infection. Transfections of HeLa cells were conducted with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. For Act1 reconstitution into Act1 −/− MEFs and transfection of LSL-HA-Act1 knock-in/UBC-Cre-ERT2 MEFs, cells were either infected by retroviral supernatant as described previously 12 or transfected with an Amaxa nucleofector apparatus. Supernatants for retroviral infections were obtained by transfecting Phoenix cells with 5 μ g of retroviral constructs derived from pMSCV-IRES-GFP for 48 h. MEFs were infected with viral supernatant for 24 h, and GFP-positive cells were sorted out to establish stable cell lines for downstream assays. Transfections with the Amaxa nucleofector apparatus were performed according to the manufacturer's instructions (program A-023, Amaxa MEF Nucleofector Kit 1).
Quantitative real-time PCR.
Total RNA was isolated with TRIzol reagent (Invitrogen). The cDNA was synthesized with random hexamers (Applied Biosystems) and M-MLV reverse transcriptase (Promega). Real-time PCR was performed with a SYBR Green PCR Master Mix kit (Applied Biosystems). All gene expression results were calculated by the change in cycling threshold (Δ Ct) method, where Δ Ct = Ct of target gene − Ct of Actb (encoding β -actin), and are presented as 2 -ΔCt . The primers used for qPCR are listed in Supplementary Table 1 .
Constructs. For GFP reporter constructs, full-length cDNAs of hAct1, hDcp1a, hIKKi, hTBK1 and hTIA1 were cloned into the pEGFP-N1 vector (Clontech). For RFP reporter constructs, full-length cDNAs of hAct1, hIRAK1 and hDcp1a were cloned into pDsRed-Monomer-Hyg-N1 vector (Clontech). For constructs V5-hDcp1a, FLAG-hDcp1a, FLAG-hDcp2, FLAG-hIRAK1, V5-IL-17RA, HA-hAct1 and HA-hAct1Δ SEFIR, the cDNAs with the corresponding tag were cloned into the pcDNA3.1 vector. Wild-type (FLAG-hAct1) and Act1 internal-deletion mutants of the SEFIR domain (designated Δ SEFIR1 to Δ SEFIR5 (based on the five exons that encode regions of the SEFIR domain: 410 to 439, 440 to 462, 463 to 501, 502 to 526, and 527 to 552) and Δ SEFIR (deletion of amino acid residues 391-537)), receptor binding mutant 41 (H472D), TRAF6 binding mutant 41 (deletion of amino acid residues [38] [39] [40] [41] [42] [333] [334] [335] [336] [337] or RNA binding mutant (SEFIR1 + 5mt) (K407A, K524A, K526A and K527A) were FLAG-tagged and cloned into pcDNA3.1. Retroviral Act1-WT and Act1-mutant constructs derived from pMSCV-IRES-GFP were as previously described 6, 12, 24 .
Constructs for in vitro transcription. Fragments containing the 3′ -UTR sequences of CXCL1 220 (nt 720-940) and the truncated fragments CXCL1 120 (nt 780-900), CXCL1 110 (nt 780-890), CXCL1 90 (nt 790-880), CXCL1 80 (nt 800-880), CXCL1 70 (nt 800-870); SBE WT (CXCL1 47, nt 810-857), SBE mutant B (CXCL1 47, nt 810-857 with altered sequence shown in Supplementary  Table 2 ), SBE mutant C (CXCL1 47, nt 810-857 with altered sequence shown in Supplementary Table 2 ), stem-loop B (CXCL1, 800-835) and stem-loop C (CXCL1, 830-856), as well as the 3′ -UTR sequences of TNF (nt 1361-1507), GM-CSF (nt 513-785) and GPx4 (nt 775-962), were generated by PCR and cloned into the pGEM-3ZF(+ ) vector (Promega) through the EcoRI and BamHI sites. The plasmid containing the 3′ UTR of mouse TNF was a kind gift from V. Heissmeyer. All mutations were introduced with a QuikChange II Site Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. Primers used for generating all constructs are listed in Supplementary Table 2 .
In vitro transcription and cap labeling. REMSA radiolabeled 3′ -UTR RNA probes were synthesized from BamHI-linearized plasmid templates (described in 'Constructs for in vitro transcription') with T7 RNA polymerase and 1 mM GTP, 1 mM ATP, 1 mM CTP, 0.005 mM UTP and 25 μ Ci of 32 P-labeled UTP for 3 h at 37 °C. Probes were DNase I treated for 20 min and then phenol-chloroform extracted. The aqueous phase was passed through a Micro Bio-Spin P30 column according to the manufacturer's instructions (Bio-Rad). For in vitro decapping, probes were synthetized as above, but with unlabeled 1 mM CTP, then DNase treated and purified. Cap labeling was performed with the Vaccinia Capping System (NEB) according to the manufacturer's instructions in the presence of [α -32 P]GTP.
For RNase footprinting experiments, cold synthetic transcripts were dephosphorylated with SuperSAP (Affymetrix), purified and resuspended in nuclease-free water. Dephosphorylated transcripts were end-labeled in the presence of [γ -32 P]ATP (3,000 Ci/mmol; Perkin Elmer Easy Tides) and T4 PNK (NEB) at 20 units/pmol RNA. The transcripts were gel purified on 8% acrylamide (19:1)/7 M urea gels and eluted in 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, pH 8, and 300 mM NaOAc, pH 5.5, at 4 °C overnight. Purified RNA was stored in 10 mM Tris-HCl, pH 7.5, at -20 °C.
RNase footprinting. 32 P-end-labeled CXCL1 SBE RNA was heated to 95 °C and slow cooled to room temperature. The RNA (2.5 nM) was incubated in L30 binding buffer (30 mM Tris-HCl, pH 8.0, 75 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 0.04 μ g/μ l BSA (NEB), 10% glycerol and 50 ng/μ l yeast tRNA) with or without mouse Act1 SEFIR protein (1.5 μ M) at 30 °C for 10 min. Reactions were cooled to room temperature over a 2-min period and then placed at 22 °C for 2-5 min. The indicated amounts of RNase T1, A or V1 (Ambion) were added to the appropriate samples and incubated at 22 °C for 5 min. Enzymatic reactions were quenched with 30 μ l Inactivation/Precipitation buffer (Ambion) and purified according to the manufacturer's directions. Samples were resuspended in 10 μ l of loading buffer (Ambion), heat denatured at 95 °C for 5 min and separated in a denaturing 8% (19:1) polyacrylamide/7 M urea gel. The dried gels were visualized with a phosphorimager or on film.
Sequencing ladders were prepared by incubating 32 P-end-labeled Cxcl1 SBE RNA (2.5 nM) in 1× Sequencing Buffer (Ambion) supplemented with 50 ng/μ l yeast tRNA. The RNAs were incubated at 50 °C for 5 min and cooled to 22 °C, and the indicated amounts of RNases T1 and A were then added. The samples were incubated, quenched and purified as described above. Alkali ladders were prepared by incubating 32 P-end-labeled PHGPx SECIS RNA (2.5 nM) in 100 mM NaOH, 2 mM EDTA, pH 8.0, and 2 μ g/μ l yeast tRNA at 37 °C for 3 min, to which 0.2 M Tris-HCl, pH 8.0 (final) was added. The samples were frozen on dry ice and combined with an equal volume of loading buffer.
RNA electrophoretic mobility shift assay (REMSA). Increasing amounts of purified protein and labeled probes (10 fmol; described in 'In vitro transcription') were combined in the binding buffer for 30 min. The final REMSA binding-buffer concentrations were 140 mM KCl, 10 mM HEPES, pH 7.9, 5% glycerol, 1 mM DTT and 0.33 mg/ml tRNA. The reaction was further supplemented with 15 μ g salmon sperm DNA to decrease nonspecific interactions from the lysate. Complexes were resolved on either 4% or 6% nondenaturing polyacrylamide gels. The gels were dried, and the appearance of complexes was visualized by exposure to BioMax MR film. Dissociation constants were determined by quantifying the protein-bound fractions in ImageJ software and were plotted against protein concentration (nM). K d values were extracted from plots fitted to a hyperbolic function in GraphPad Prism software (OriginLab).
SBE aptamer competition.
The purified recombinant His-MBP-Act1 SEFIR (200 ng) was incubated with the 32 P-labeled Csf2 and Tnf 3′ -UTR probes for 15 min to form protein-RNA complexes. Cold RNAs were added at 0-, 25-, 50-, 100-or 200-fold molar excess over the probe for an additional 10 min, then subjected to REMSA. SBE WT (Cxcl1 47, as indicated in Fig. 3a) and SBE mutant C were used in the competition assay ( Fig. 7a and d) . IC 50 values were calculated as the concentration of aptamers that displaced 50% of bound Cxcl1 220 probe from the Act1 SEFIR.
Protein modeling. The structure model of Act1 SEFIR was built in SWISS-Model (http://swissmodel.expasy.org/), by using the crystal structure of IL-17RA SEFIR as the template 46 (PDB 4NUX).
Surface plasmon resonance. The SPR binding affinity was analyzed on a BIAcore 3000 instrument. The biotinylated RNA was immobilized on a streptavidin-coated a tetracycline-response element. In the absence of tetracycline or its analog doxycycline, the tetracycline transactivator drives transcription of the reporter mRNA. After the addition of doxycycline to the culture medium, transcription is abolished, thus allowing for the rate of reporter mRNA decay to be measured. We treated the transfected cells with doxycycline to allow reporter Cxcl1mRNA to decay for 0, 45 and 90 min, and assessed remaining reporter mRNA encoding Cxcl1 220 and Gapdh mRNA. Total RNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer's instructions, then subjected to RT-PCR. The values were normalized to those of Gapdh mRNA.
Microscopy. Immunohistochemistry staining was recorded with an OLYMPUS DP71 digital camera attached to an Olympus BX41 microscope. Fluorescence images were captured with a Leica confocal Microscope (Lerner Institute Imaging Core). As a routine practice, three independent plates of cells were analyzed for quantification, with a total of 50 cells analyzed from each plate. Corresponding author(s): Xiaoxia Li Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 2. Data exclusions
Describe any data exclusions. no data was excluded
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
For intracellular imaging quantification 50 randomly cells chosen from 3 independent plates of were quantified. Every experiment shown was repeated at least three or two times as indicated in the figure legends. All of replicate experiments produced consistent, statistically significant data, as indicated in figure legends. For experiments involving purified proteins at least three batches of independently purified proteins were tested. For experiments involving cell lines at least three different batches of cells were tested.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Before treatment mice were randomly divided into experimental groups (8-weekold female C57BL/6J mice (n=6 mice/group)
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
To reduce potential experimental bias, the identity of cell lines (MEFs expressing Act1 WT and its variants) identity of RNA aptamers, purified proteins as well as RNA probes (for REMSA) was blinded from the researchers performing the validation experiments. These identities were only revealed at the final data analysis stage. In case of the in vivo study RNA aptamer identity was blinded from researcher performing intranasal and intradermal injections. For the stage of tissue and BAL 2 nature research | life sciences reporting summary November 2017 fluid collection group allocation was concealed. These identities were only revealed at the final data analysis stage. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Graphpad Prism 6.0, Microsfot Excel, ImageJ, BIAcore 3000.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party. c. Report whether the cell lines were tested for mycoplasma contamination.
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Cell lines were tested for mycoplasma contamination and were not contaminated.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
All mice used for this study were on a C57BL/6 background. For special strains, the experimental mice were bred in house in SPF condition. Genotypes of these strains were confirmed using PCR analysis. For derivation of MEFs, embryos (E13.5 to E14.5) were used. Litter mates of the same gender carrying with control genotypes were used to derive control MEFs. Female mice between 6 to 8 weeks old purchased from Jackson lab were used for in vivo experiment (Figure 8 ).
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
